The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

NHS Quality Improvement Scotland
Record ID 32002000510
Authors' objectives:

This Understanding HTBS Advice is about the HTBS Comment on Guidance published by the National Institute of Clinical Excellence (NICE) on the use of these treatments. It has been produced to explain this HTBS Advice to people who are not healthcare workers, particularly people with colorectal cancer and their carers, and explains what the HTBS Comment means for people with colorectal cancer and how HTBS formed its Comment about the use of these treatments. Much of the information in this booklet comes from a leaflet published by NICE about the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (March 2002).

Authors' recommendations: HTBS supports the NICE Technology Appraisal Guidance on the use of chemotherapy agents in the treatment of advance colorectal cancer. In summary: - For patients who have not responded to treatment containing 5-fluorouracil (5FU), irinotecan as a single therapy is recommended. - For patients who have metastases that occur only in the liver and that may become operable after treatment, oxaliplatin in combination with 5FU and folinic acid (FA) should be considered for use as first-line therapy. - Not recommended for routine use: - Raltitrexed - Irinotecan in combination with 5FU/FA - Oxaliplatin in combination with 5FU/FA (apart from those with liver metastases as indicated above). - It is likely that patients currently receiving irinotecan or oxaliplatin in combination with 5FU/FA or raltitrexed could suffer loss of well being if their treatment is discontinued at a time they did not anticipate. Because of this, patients and their consultants may wish to continue therapy until they consider it is appropriate to stop.
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Scotland, United Kingdom
MeSH Terms
  • Irinotecan
  • Oxaliplatin
  • Colorectal Neoplasms
  • Drug Therapy, Combination
  • Treatment Outcome
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboxylic Ester Hydrolases
  • Organoplatinum Compounds
Organisation Name: Health Technology Board for Scotland
Contact Address: Delta House, 50 West Nile Street Glasgow G1 2NP Scotland United Kingdom Tel: +44 141 225 6988; Fax: +44 141 221 3262
Contact Name:
Contact Email:
Copyright: Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS))
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.